Category: AHRQ

A qualitative analysis of outpatient medication use in community settings: observed safety vulnerabilities and recommendations for improved patient safety.

Agency for Healthcare Research and Quality

Lyson HC, Sharma AE, Cherian R, et al. J Patient Saf. 2019 Mar 13; [Epub ahead of print].

Using incident reports to assess communication failures and patient outcomes.

Agency for Healthcare Research and Quality

Umberfield E, Ghaferi AA, Krein SL, Manojlovich M. Jt Comm J Qual Patient Saf. 2019 Mar 29; [Epub ahead of print].

Improving employee voice about transgressive or disruptive behavior: a case study.

Agency for Healthcare Research and Quality

Dixon-Woods M, Campbell A, Martin G, et al. Acad Med. 2019;94:579-585.

Caring for the Caregiver: The RISE Program.

Agency for Healthcare Research and Quality

Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Maryland Patient Safety Center. May 30, 2019; Armstrong Institute for Patient Safety and Quality, Baltimore, MD.

Community Pharmacy Survey on Patient Safety Culture: 2019 User Comparative Database Report.

Agency for Healthcare Research and Quality

Famolaro T, Yount ND, Hare R, et al. Rockville, MD: Agency for Healthcare Research and Quality; April 2019. AHRQ Publication No. 19-0033.

Teaching patient safety in global health: lessons from the Duke Global Health Patient Safety Fellowship.

Agency for Healthcare Research and Quality

Johnston BE, Lou-Meda R, Mendez S, et al. BMJ Glob Health. 2019;4:e001220.

How to deliver safer and effective patient care: tips for team leaders and educators.

Agency for Healthcare Research and Quality

Shah BJ. Gastroenterology. 2019;156:852-855.

Potential consequences of patient complications for surgeon well-being: a systematic review.

Agency for Healthcare Research and Quality

Srinivasa S, Gurney J, Koea J. JAMA Surg. 2019 Mar 27; [Epub ahead of print].

Will human factors restore faith in the GMC?

Agency for Healthcare Research and Quality

Morgan L, Benson D, McCulloch P. BMJ. 2019;364:l1037.

FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering.

Agency for Healthcare Research and Quality

Silver Spring, MD: US Food and Drug Administration; April 9, 2019.